查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018443

神经血管器材市场：按产品类型、适应症、最终用户和通路分類的全球市场预测，2026-2032年

Neurovascular Devices Market by Product Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经血管器械市场价值将达到 55.9 亿美元，到 2026 年将成长至 60.1 亿美元，到 2032 年将达到 93.3 亿美元，复合年增长率为 7.57%。

主要市场统计数据
基准年 2025 55.9亿美元
预计年份：2026年 60.1亿美元
预测年份 2032 93.3亿美元
复合年增长率 (%) 7.57%

对神经血管设备生态系统进行清晰的管理概述，使临床创新与商业性和监管决策标准保持一致。

神经血管器械领域正处于快速临床创新与医疗系统监管日益加强的交汇点，这要求经营团队在策略选择上做出清晰的决策。器械设计、与影像技术的融合以及术前术后护理的进步，重新定义了临床医生的期望，并拓展了适应症。同时，保险公司和采购负责人也越来越重视可验证的疗效和成本效益。相关人员现在需要简洁明了、基于证据的总结，将技术能力与临床终点和商业性可行性联繫起来。

技术成熟度、监管预期和程序标准化如何重塑采用路径和竞争优势？

神经血管器械市场格局正经历一场变革，其驱动力主要来自三大面向：技术成熟、流程标准化、支付方期望的转变。医疗设备的改进越来越依赖真实世界的性能数据和计算模型，加速了从一次性原型产品向临床稳定平台的转变。精细化的流程和标准化的培训路径正在降低患者预后的差异性，并将应用范围从专科转诊中心扩展到更广泛的医疗机构。

重组采购和定价策略：近期关税措施对供应链、采购和伙伴关係的累积影响。

近期关税措施和贸易政策调整给神经血管器械供应链带来了明显的压力，製造商和供应商必须应对这些压力。影响原料、零件和成品进口的关税推高了部分製造商的采购成本，促使他们更加重视国内生产和策略采购。为此，一些製造商正在重新审视与供应商的合同，并探索近岸外包和区域性製造地，以维持利润率并确保供应的连续性。

详细的細項分析揭示了产品架构、临床适应症、医疗保健环境和通路如何驱动不同的采用和购买行为。

神经血管器械领域的細項分析揭示了独特的市场推广路径以及与商业性效用。在血流导引装置方面，诸如Pipeline栓塞平台、丝状结构和Surpass架构系统等装置在输送和血管壁黏附性方面展开竞争。同时，微导管依靠亲水涂层和聚四氟乙烯（PTFE）涂层来优化其在弯曲脑血管内的导航性能。弹簧圈技术涵盖从裸金属到生物活性和水凝胶增强型等多种类型，旨在提高动脉瘤闭塞的持久性。支架分为编织型和雷射切割型，以平衡径向强度、柔软性和血管贴合性。

决定全球主要医疗保健地区差异化商业策略的跨区域监管、报销和生产趋势。

区域趋势对神经血管器械产业的监管路径、报销框架和生产策略有显着影响，美洲、欧洲、中东和非洲以及亚太地区之间存在显着差异。在美洲，医院系统的整合以及对真实世界数据的重视正在影响报销讨论，并提升卫生经济学在采购谈判中的重要性。该地区的医疗机构通常优先考虑那些能够提高手术效率并缩短住院时间的技术，这反过来又会影响商业性讯息和临床试验设计。

产品差异化、策略联盟和卓越营运如何塑造竞争优势和长期临床医生偏好。

神经血管器材领域的竞争格局围绕着产品差异化、实证医学证据的累积以及旨在拓展核心技术临床效用的策略联盟。成熟的器械製造商通常利用其丰富的产品系列，提供包含器械、影像软体和培训服务的整合解决方案，从而降低医院系统采用整合解决方案的门槛。相较之下，专业公司和Start-Ups通常专注于有限的创新方向，例如新型血流旁路支架或先进的线圈化学技术，透过建立临床验证点来吸引合作伙伴和收购者的兴趣。

为医疗设备製造商和供应商提供实用策略指南，以协调临床证据、製造韧性和客製化商业化，从而加速部署。

产业领导企业应采取多管齐下的策略，将研发重点与可证实的临床价值结合，同时增强价值链的韧性和商业性灵活性。首先，应优先进行临床证据项目，以解答支付方和医院决策者关于疗效和成本抵销的问题，确保研究终点与实际决策标准相符。其次，将资料收集和分析功能整合到医疗器材和上市后註册系统中，以持续产生效能洞察，从而支援报销讨论和产品迭代改进。

采用严谨的混合方法研究途径，结合专家访谈、监管分析和临床证据整合，为策略决策提供支援。

本报告的研究结合了对临床专业人员、采购经理和医疗设备公司高阶主管的定性访谈，以及对监管指南和同行评审临床文献的系统分析。主要访谈对象包括介入神经神经科、神经介入放射科医生、医院采购经理和产品开发经理，揭示了公开资讯来源中未一致的营运实际情况和决策因素。调查团队将访谈结果与监管申报文件、医疗设备附加檔和临床註册结果进行交叉比对，以检验观察到的趋势并检验新出现的推广障碍。

透过协调创新、证据生成和营运韧性，简洁地整合策略挑战，以确保可持续的临床部署。

本分析的整体结果清楚地表明，相关人员需要迅速采取谨慎行动。器械设计和手术流程的技术进步正在拓展临床选择，但这些技术的成功应用将取决于可证实的疗效、价格透明度和供应可靠性。监管机构的期望和支付方的审查日益凸显了整合证据策略和上市后资料收集的重要性，而贸易政策的转变则进一步强化了多元化采购和区域製造策略的价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 神经血管器材市场：依产品类型划分

  • 栓塞装置
    • 线圈栓塞装置
    • 液体栓塞系统
    • 血流灌注支架
  • 血管成形术和支架置入系统
  • 神经血栓除去装置
    • 血栓摘取支架
    • 吸力装置
  • 支援和存取设备
    • 微导管
    • 导管导引线
    • 球囊导管

第九章：神经血管器材市场：依适应症划分

  • 脑动脉瘤
  • 缺血性中风
  • 动静脉畸形（AVM）和瘻管
  • 颈动脉和颅内动脉狭窄
  • 出血性中风

第十章 神经血管器材市场：依最终用户划分

  • 门诊手术中心
    • 医院相关设施
    • 独立设施
  • 医院
  • 专科诊所
  • 研究机构和学术机构

第十一章：神经血管器材市场：依通路划分

  • 直销
  • 线上销售
  • 第三方经销商

第十二章 神经血管器材市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 神经血管器材市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 神经血管器材市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国：神经血管器材市场

第十六章 中国：神经血管器械市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Stryker Corporation
  • Medtronic plc
  • Johnson & Johnson
  • Penumbra, Inc.
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • ASAHI INTECC CO., LTD.
  • Kaneka Corporation
  • BALT Group
  • Acandis GmbH
  • Phenox GmbH
  • Integer Holdings Corporation
  • Imperative Care, Inc.
  • Rapid Medical Ltd.
  • Anaconda Biomed SL
  • ArtVentive Medical Group, Inc.
  • Endologix Inc.
  • Evasc Medical Systems Corp
  • iVascular SLU
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co.,Ltd.
  • Medical Murray, Inc.
  • NeuroVasc Technologies Inc.
  • Nventric, Inc.
  • Scientia Vascular, Inc.
  • Secant Group, LLC
  • Vesalio, LLC
  • Zeus Company LLC
  • ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Product Code: MRR-0360AB17E1FE

The Neurovascular Devices Market was valued at USD 5.59 billion in 2025 and is projected to grow to USD 6.01 billion in 2026, with a CAGR of 7.57%, reaching USD 9.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.59 billion
Estimated Year [2026] USD 6.01 billion
Forecast Year [2032] USD 9.33 billion
CAGR (%) 7.57%

A clear executive overview of the neurovascular devices ecosystem that aligns clinical innovation with commercial and regulatory decision criteria

The neurovascular devices domain sits at the intersection of rapid clinical innovation and heightened health system scrutiny, demanding clarity for executives making strategic choices. Advances in device design, imaging integration, and periprocedural care have reshaped clinician expectations and broadened procedural indications, while payers and procurement officers increasingly demand demonstrable outcomes and cost-effectiveness. Stakeholders now require concise, evidence-based syntheses that link technological capabilities to clinical endpoints and commercial viability.

Clinical momentum around minimally invasive approaches and imaging-guided interventions has raised the bar for device performance and operator training. Concurrently, healthcare providers face pressure to optimize patient throughput and justify capital and consumable expenditures through measurable improvements in morbidity and length of stay. Investors and corporate strategists are therefore looking for analyses that translate procedural innovation into sustainable adoption pathways. This introduction frames the broader report by aligning clinical, regulatory, and commercial vectors that will determine which technologies and providers gain enduring traction in the neurovascular ecosystem.

Throughout the subsequent sections, the report zeroes in on the major drivers of change, the segmentation patterns that influence procurement and reimbursement decisions, and the regional and competitive dynamics that shape market entry and expansion. The aim is to provide leadership teams with a coherent narrative that guides prioritization and investment decisions in a complex, fast-evolving field.

How technological maturation, regulatory expectations, and procedural standardization are reshaping adoption pathways and competitive advantages

The landscape for neurovascular devices is experiencing transformative shifts driven by three converging forces: technological maturation, procedural standardization, and shifting payer expectations. Device iterations are increasingly informed by real-world performance data and computational modeling, which in turn accelerate the transition from single-use prototypes to clinically robust platforms. Procedural refinements and standardized training pathways are reducing variability in patient outcomes, pushing adoption from niche referral centers toward broader institutional settings.

Regulatory authorities are also evolving their expectations for clinical evidence and post-market surveillance, prompting manufacturers to embed data-generation capabilities into device lifecycles. This regulatory pressure is catalyzing partnerships between device makers and imaging or software vendors, as stakeholders seek integrated solutions that offer measurable outcome improvements and streamlined workflows. In addition, supply chain resilience and manufacturing scalability have become strategic priorities; leaders are investing in reagent sourcing strategies and dual-sourcing to mitigate external shocks.

The cumulative effect is a marketplace where differentiation increasingly rests on clinical evidence, procedural efficiency, and the capacity to demonstrate value to payers and hospital procurement committees. These shifts have practical implications for product development roadmaps, commercialization models, and collaboration strategies, and they necessitate that companies recalibrate R&D priorities and market entry timing to align with both clinical practice patterns and reimbursement realities.

The cumulative supply chain, procurement, and partnership implications of recent tariff activity that are reshaping sourcing and pricing strategies

Recent tariff measures and trade policy adjustments have created discernible pressure points across the neurovascular devices supply chain that manufacturers and providers must navigate. Tariffs influencing raw material imports, componentry, and finished devices have raised procurement costs for some manufacturers and incentivized onshore manufacturing and strategic sourcing arrangements. In response, several manufacturers have re-evaluated supplier contracts and explored nearshoring and regional manufacturing hubs to preserve margin integrity and supply continuity.

For hospitals and ambulatory centers, the pass-through effects of increased procurement costs have pressured capital allocation decisions and brought greater scrutiny to device utilization and cost-per-case metrics. As a result, purchasing departments are intensifying competitive bidding and lengthening vendor qualification cycles, while clinical teams are being asked to justify device selection through evidence demonstrating improved clinical outcomes or reduced downstream costs. At the same time, tariffs have heightened the importance of flexible distribution channels; organizations are diversifying between direct sales, third-party distributors, and digital procurement platforms to retain negotiating leverage.

Importantly, the policy environment has also influenced strategic partnerships and licensing arrangements. Firms with manufacturing footprints outside tariff-impacted jurisdictions have gained relative logistical advantages, while others have accelerated transfer agreements and regional licensing to maintain market access. Moving forward, stakeholders who proactively optimize sourcing, adapt pricing strategies, and strengthen regional logistics will be better positioned to absorb policy-induced cost variability and sustain supply reliability.

In-depth segmentation analysis revealing how product architectures, clinical indications, care settings, and distribution routes drive distinct adoption and procurement behaviors

Segmentation within the neurovascular devices space reveals distinct pathways to adoption and distinct commercial imperatives tied to product type, clinical indication, end user, and distribution channel. Product typology spans flow diversion devices, microcatheters, neurovascular coils, and neurovascular stents, each carrying unique engineering constraints and clinical utility. Within flow diversion, devices like pipeline embolization platforms, silk-style constructs, and surpass-architecture systems compete on deliverability and wall apposition, while microcatheters rely on coatings such as hydrophilic and PTFE to optimize navigation through tortuous cerebral vasculature. Coil technologies range from bare metal to bioactive and hydrogel-enhanced variants that aim to improve aneurysm occlusion durability. Stent families, divided between braided and laser-cut architectures, balance radial strength against flexibility and vessel conformability.

Clinical indication segmentation further differentiates adoption dynamics across arteriovenous malformation interventions, intracranial aneurysm treatments, intracranial stenosis management, and ischemic stroke therapies. AVM interventions pivot on the selection of glue embolic agents versus Onyx-based systems, whereas intracranial aneurysm care involves choices among endovascular coiling, flow diversion strategies, and stent-assisted coiling, with device selection influenced by aneurysm morphology and clinical risk profiles. Intracranial stenosis care leans on balloon angioplasty and stenting techniques, and ischemic stroke pathways include intraarterial thrombolysis and mechanical thrombectomy systems, each demanding specific device compatibilities and imaging workflows.

End-user segmentation highlights differentiated purchasing behaviors across ambulatory surgical centers, hospitals, and specialty clinics. Ambulatory centers vary by affiliation status, hospitals range from primary community facilities to tertiary care centers with complex neurointerventional programs, and specialty clinics encompass interventional radiology and neurology clinics that may act as referral hubs. Distribution channels also cast significant influence on market access and service models, with direct sales supported by field representatives and institutional contracts, online sales through e-commerce platforms and manufacturer web portals, and third-party distributors spanning retail and wholesale networks. Navigating this layered segmentation requires tailored value propositions for each stakeholder, aligning device features with procedural requirements, reimbursement realities, and procurement models.

Cross-regional regulatory, reimbursement, and manufacturing dynamics that determine differentiated commercial strategies across major global healthcare regions

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and manufacturing strategies across the neurovascular devices landscape, with material differences observable between the Americas, Europe, Middle East & Africa, and Asia-Pacific jurisdictions. In the Americas, consolidation in hospital systems and a strong emphasis on real-world evidence are shaping reimbursement discussions and elevating the importance of health economics in procurement conversations. Providers in this region often prioritize technologies that demonstrate procedural efficiency and the potential to reduce length of stay, which in turn affects commercial messaging and clinical trial design.

In Europe, Middle East & Africa, regulatory harmonization efforts and variable reimbursement environments create both opportunities and complexities. Manufacturers must navigate a mosaic of national health systems and payer requirements, while also capitalizing on centralized procurement opportunities for cross-border tenders. Meanwhile, the Asia-Pacific region presents a mix of rapidly expanding procedural volumes and differing regulatory maturation, prompting strategies that balance cost competitiveness with scalable clinical education programs. Localization of manufacturing and targeted clinical partnerships have become common tactics in the region to accelerate adoption while addressing pricing sensitivity.

Across all regions, cross-border logistics, intellectual property considerations, and regional training capabilities inform both entry strategies and partnership models. Stakeholders that invest early in region-specific regulatory planning, localized clinical evidence generation, and supply chain redundancy tend to secure more reliable market access and foster deeper clinician engagement, thereby improving the odds of sustained adoption across geographically diverse healthcare ecosystems.

How product differentiation, strategic alliances, and operational excellence are shaping competitive advantage and long-term clinician preference

Competitive dynamics among companies active in the neurovascular devices sector center on product differentiation, evidence generation, and strategic collaborations that extend the clinical utility of core technologies. Established device manufacturers often leverage broad portfolios to offer bundled solutions that include devices, imaging software, and training services, thereby lowering the barrier to adoption for hospital systems seeking integrated offerings. In contrast, specialized firms and startups typically focus on narrow innovation vectors-such as novel flow diversion scaffolds or advanced coil chemistries-to establish clinical proof points and attract partnership or acquisition interest.

Strategic transactions, licensing agreements, and co-development partnerships are prominent routes to scale technology and accelerate market entry, particularly where regulatory or clinical validation timelines are lengthy. Companies that align with leading neurointerventional centers to co-design procedural workflows gain early adopters and real-world data streams that support payer discussions. Similarly, alliances with imaging and software vendors enable device makers to incorporate analytics and outcome tracking into their value proposition.

Operational excellence remains a differentiator; firms that invest in manufacturing quality systems, robust post-market surveillance, and responsive field support tend to sustain clinician trust and institutional contracts. Pricing flexibility, bundled contracting, and outcomes-based agreements are increasingly employed by companies to address procurement complexity and to demonstrate commitment to shared patient outcome goals. Ultimately, the firms that combine technical differentiation with clear pathways to evidence generation and dependable service delivery will be best positioned to capture long-term clinical preference.

A pragmatic strategic playbook for device makers and providers to align clinical evidence, manufacturing resilience, and tailored commercialization to accelerate adoption

Industry leaders should adopt a multi-pronged strategy that aligns R&D priorities with demonstrable clinical value, while simultaneously reinforcing supply chain resilience and commercial agility. First, prioritize clinical evidence programs that are designed to answer payer and hospital decision-maker questions about outcomes and cost offsets, ensuring that study endpoints map to real-world decision criteria. Second, embed data capture and analytics capabilities into devices and post-market registries to generate ongoing performance insights that support reimbursement discussions and iterative product improvements.

Third, diversify manufacturing and procurement footprints to mitigate policy or logistic disruptions, and consider regional partnerships or licensing to preserve market continuity. Fourth, tailor go-to-market approaches to end-user segmentation by creating differentiated value propositions for ambulatory centers, tertiary hospitals, and specialty clinics that reflect each setting's clinical workflows and purchasing constraints. Fifth, expand commercial models to include flexible contracting, bundled offerings, and training partnerships that reduce adoption friction and align incentives between providers and manufacturers.

Finally, invest in collaborative relationships with imaging and software providers, clinical leaders, and distribution partners to create comprehensive procedural solutions. By coupling targeted clinical programs with resilient operations and adaptive commercialization, organizations can both accelerate adoption and demonstrate long-term value to stakeholders across the neurovascular ecosystem.

A rigorous mixed-methods research approach combining expert interviews, regulatory analysis, and clinical evidence synthesis to support strategic decision-making

The research underpinning this report synthesizes primary qualitative engagement with clinical experts, procurement leaders, and device executives alongside systematic analysis of regulatory guidance and peer-reviewed clinical literature. Primary interviews were conducted with interventional neurologists, neurointerventional radiologists, hospital purchasing managers, and product development leaders to surface operational realities and decision drivers that do not consistently appear in published sources. The research team triangulated interview findings with regulatory filings, device labeling information, and clinical registry outcomes to validate observed trends and to identify emerging adoption barriers.

Secondary research included a structured review of clinical trials, systematic reviews, and health technology assessment reports to establish the clinical context for device usage across indications. Supply chain analysis drew on publicly available trade data, manufacturing footprints, and corporate disclosures to map likely tariff and sourcing exposure points. In addition, the methodology incorporated scenario planning to examine how supply chain, reimbursement, and regulatory permutations could affect procurement dynamics, without projecting specific market sizes or forecasts.

Throughout, the methodology emphasized reproducibility and transparency. Interview protocols and inclusion criteria were standardized, and data sources were cross-referenced to reduce bias. The combination of qualitative insight and document-based verification yields a robust evidence base designed to inform strategy and operational planning for stakeholders engaged in the neurovascular devices domain.

A concise synthesis of strategic imperatives that align innovation, evidence generation, and operational resilience to secure durable clinical adoption

The cumulative insights presented across this analysis paint a clear imperative for stakeholders to act with both speed and deliberation. Technological progress in device design and procedural practice is expanding clinical options, but adoption will hinge on demonstrable outcomes, pricing clarity, and supply reliability. Regulatory expectations and payer scrutiny are elevating the importance of integrated evidence strategies and post-market data capture, while trade policy shifts are reinforcing the value of diversified sourcing and regional manufacturing strategies.

For decision-makers, the path forward requires aligning product development with the information needs of clinicians, payers, and hospital purchasers. This means prioritizing clinical programs that generate actionable outcomes data, designing commercial models that reduce procurement friction, and investing in service capabilities that support training and device lifecycle management. Organizations that combine technical differentiation with operational resilience and evidence-driven commercialization will create durable advantages and clearer pathways to clinical preference.

In sum, the neurovascular devices landscape presents significant opportunity, but realizing that opportunity demands coordinated strategies across R&D, regulatory planning, manufacturing, and go-to-market execution. Stakeholders who act now to shore up evidence generation, supply chain flexibility, and tailored commercial engagement will be best positioned to translate innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Devices Market, by Product Type

  • 8.1. Embolization Devices
    • 8.1.1. Coil Embolization Devices
    • 8.1.2. Liquid Embolic Systems
    • 8.1.3. Flow Diversion Stents
  • 8.2. Angioplasty & Stenting Systems
  • 8.3. Neurothrombectomy Devices
    • 8.3.1. Stent Retrievers
    • 8.3.2. Aspiration/Suction Devices
  • 8.4. Support & Access Devices
    • 8.4.1. Microcatheters
    • 8.4.2. Guidewires
    • 8.4.3. Balloon Catheters

9. Neurovascular Devices Market, by Indication

  • 9.1. Cerebral Aneurysms
  • 9.2. Ischemic Stroke
  • 9.3. Arteriovenous Malformations (AVMs) & Fistulas
  • 9.4. Carotid Artery & Intracranial Stenosis
  • 9.5. Hemorrhagic Stroke

10. Neurovascular Devices Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Hospital Affiliated Centers
    • 10.1.2. Independent Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics
  • 10.4. Research Laboratories & Academic Institutions

11. Neurovascular Devices Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Online Sales
  • 11.3. Third Party Distributors

12. Neurovascular Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neurovascular Devices Market

16. China Neurovascular Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Stryker Corporation
  • 17.6. Medtronic plc
  • 17.7. Johnson & Johnson
  • 17.8. Penumbra, Inc.
  • 17.9. Terumo Corporation
  • 17.10. MicroPort Scientific Corporation
  • 17.11. ASAHI INTECC CO., LTD.
  • 17.12. Kaneka Corporation
  • 17.13. BALT Group
  • 17.14. Acandis GmbH
  • 17.15. Phenox GmbH
  • 17.16. Integer Holdings Corporation
  • 17.17. Imperative Care, Inc.
  • 17.18. Rapid Medical Ltd.
  • 17.19. Anaconda Biomed S.L.
  • 17.20. ArtVentive Medical Group, Inc.
  • 17.21. Endologix Inc.
  • 17.22. Evasc Medical Systems Corp
  • 17.23. iVascular S.L.U.
  • 17.24. Koninklijke Philips N.V.
  • 17.25. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 17.26. Medical Murray, Inc.
  • 17.27. NeuroVasc Technologies Inc.
  • 17.28. Nventric, Inc.
  • 17.29. Scientia Vascular, Inc.
  • 17.30. Secant Group, LLC
  • 17.31. Vesalio, LLC
  • 17.32. Zeus Company LLC
  • 17.33. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LIQUID EMBOLIC SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LIQUID EMBOLIC SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LIQUID EMBOLIC SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ANGIOPLASTY & STENTING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ANGIOPLASTY & STENTING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ANGIOPLASTY & STENTING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ASPIRATION/SUCTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ASPIRATION/SUCTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ASPIRATION/SUCTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CEREBRAL ANEURYSMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CEREBRAL ANEURYSMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CEREBRAL ANEURYSMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS (AVMS) & FISTULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS (AVMS) & FISTULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS (AVMS) & FISTULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CAROTID ARTERY & INTRACRANIAL STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CAROTID ARTERY & INTRACRANIAL STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY CAROTID ARTERY & INTRACRANIAL STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROTHROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY SUPPORT & ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)